We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Almac Discovery Announces Licensing of ALM201 to Shin Poong
News

Almac Discovery Announces Licensing of ALM201 to Shin Poong

Almac Discovery Announces Licensing of ALM201 to Shin Poong
News

Almac Discovery Announces Licensing of ALM201 to Shin Poong

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Almac Discovery Announces Licensing of ALM201 to Shin Poong"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Almac Discovery has announced the licensing of its novel anti-angiogenic peptide ALM201 to Shin Poong Pharmaceutical Company Ltd for clinical development and marketing in South Korea.

Shin Poong will make an undisclosed upfront payment and pay milestones and royalties as part of the deal.

The Shin Poong programme in South Korea will run in parallel with Almac Discovery’s own development programme in Europe.

ALM201 is a novel highly potent anti-angiogenic peptide that is targeted to cells expressing CD44 and acts by inhibiting migration of vascular endothelial cells; a mechanism which clearly differentiates ALM201 from current marketed anti-angiogenics.

The compound has completed preclinical development, has a good toxicology profile and is entering Phase I/II trials in the UK.

Stephen Barr, President and Managing Director of Almac Discovery said: “We are delighted to be partnering with Shin Poong. Their work on ALM201 in South Korea will complement our own programme very well and will add significant scientific value.”

Mr. Won June Chang, CEO of Shin Poong, declared: "We are delighted to license the novel and innovative anti-cancer drug candidate from Almac Discovery and we look forward to supporting the development of this drug candidate in South Korea."

Advertisement